We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF

47 hedge funds and large institutions have $94.5M invested in VanEck Pharmaceutical ETF in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more capital invested

Capital invested by funds: $57.7M → $94.5M (+$36.7M)

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

7.82% more ownership

Funds ownership: 32.75%40.57% (+7.8%)

7% more funds holding

Funds holding: 4447 (+3)

17% less call options, than puts

Call options by funds: $1.34M | Put options by funds: $1.62M

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

Holders
47
Holders Change
+3
Holders Change %
+6.82%
% of All Funds
0.96%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
10
Reduced
14
Closed
5
Calls
$1.34M
Puts
$1.62M
Net Calls
-$274K
Net Calls Change
-$970K
Name Holding Trade Value Shares
Change
Change in
Stake
MTWSIF
1
Mivtachim The Workers Social Insurance Fund
Israel
$42.9M +$41.6M +688,500 New
Goldman Sachs
2
Goldman Sachs
New York
$16.5M
BCI
3
Brinker Capital Investments
Pennsylvania
$13.8M -$423K -7,000 -3%
OPS
4
Orion Portfolio Solutions
Nebraska
$4.84M -$5.74M -94,981 -55%
Royal Bank of Canada
5
Royal Bank of Canada
Ontario, Canada
$3.5M +$2.26M +37,430 +199%
Citadel Advisors
6
Citadel Advisors
Florida
$2.37M -$193K -3,197 -8%
Bank of America
7
Bank of America
North Carolina
$1.89M -$5.14M -85,035 -74%
Morgan Stanley
8
Morgan Stanley
New York
$1.8M +$90.2K +1,491 +5%
TRCT
9
Tower Research Capital (TRC)
New York
$827K +$804K +13,290 New
LPL Financial
10
LPL Financial
California
$746K +$175K +2,899 +32%
Commonwealth Equity Services
11
Commonwealth Equity Services
Massachusetts
$692K +$672K +11,118 New
WI
12
Wintrust Investments
Illinois
$627K -$93.7K -1,550 -13%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$570K +$554K +9,159 New
OC
14
Oppenheimer & Co
New York
$563K -$103K -1,700 -16%
UBS Group
15
UBS Group
Switzerland
$475K -$217K -3,596 -32%
BHB
16
Bank Hapoalim BM
Israel
$454K +$96.1K +1,590 +28%
DI
17
DFPG Investments
Utah
$328K -$287K -4,753 -47%
Wells Fargo
18
Wells Fargo
California
$299K -$60.5K -1,000 -17%
RJA
19
Raymond James & Associates
Florida
$267K +$4.72K +78 +2%
KIA
20
KCM Investment Advisors
California
$240K
Bank of Montreal
21
Bank of Montreal
Ontario, Canada
$135K -$18.1K -300 -12%
Osaic Holdings
22
Osaic Holdings
Arizona
$101K -$12.6K -208 -11%
GT
23
Glenmede Trust
Pennsylvania
$62K
TCM
24
Tradewinds Capital Management
Washington
$62K
NSIM
25
North Star Investment Management
Illinois
$61K +$60 +1 +0.1%

PPH Hedge Fund Activity: Q2 2020 in Review

47 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2020, worth a combined $94.5M — up 64% from $57.7M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new PPH positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 14 trimmed.

The largest buyer was Mivtachim The Workers Social Insurance Fund, opening a new position worth an estimated $41.6M. The largest seller was Orion Portfolio Solutions, cutting an estimated $5.74M.

  • 47 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2020, up from 44 in Q1 2020.
  • Funds reported $94.5M of VanEck Pharmaceutical ETF stock for Q2 2020, up 64% quarter-over-quarter.
  • 8 funds opened new VanEck Pharmaceutical ETF positions in Q2 2020 and 5 closed out, a net change of +3 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q2 2020 was Mivtachim The Workers Social Insurance Fund, an estimated $41.6M added.
  • The largest VanEck Pharmaceutical ETF seller in Q2 2020 was Orion Portfolio Solutions, an estimated $5.74M sold.

Based on aggregated 13F filings for Q2 2020.